Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1097
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-01-14
Palverafusp α (IMM2510) Receives NMPA Approval for Phase II/III Clinical Trial in Endometrial Cancer
More
2026-01-12
ImmuneOnco Biopharmaceuticals' timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis
More
2026-01-09
ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™
More

For more information

Please follow the official wechat public account